Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

被引：0
|
作者：
Means-Powell, Julie Ann
Adjei, Alex A.
Puzanov, Igor
Dy, Grace K.
Goff, Laura Williams
Ma, Wen Wee
Fetterly, Gerald J.
Michael, Shaunita A.
Chai, Feng
Lamar, Maria
Schwartz, Brian E.
Sosman, Jeffrey Alan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] ArQule Inc, Woburn, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8519
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.
    Martell, Robert E.
    Puzanov, Igor
    Ma, Wen Wee
    Santoro, Armando
    Dy, Grace K.
    Goff, Laura Williams
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Simonelli, Matteo
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.
    Puzanov, Igor
    Sosman, Jeffrey Alan
    Santoro, Armando
    Martell, Robert E.
    Dy, Grace K.
    Goff, Laura Williams
    Ma, Wen Wee
    Fetterly, Gerald J.
    Michael, Shaunita A.
    Means-Powell, Julie Ann
    Chai, Feng
    Lamar, Maria
    Strauss, Gary M.
    Zucali, Paolo A.
    Chiang, Wendy M.
    Jarboe, Jamie
    Schwartz, Brian E.
    Adjei, Alex A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)
    Lorenza, Rimassa
    Silvia, Bozzarelli
    Stefano, Cordio
    Filippo, Pietrantonio
    Laura, Toppo
    Sara, Lonardi
    Alberto, Zaniboni
    Roberto, Bordonaro
    Maria, Di Bartolomeo
    Wanda, Liguigli
    Vittorina, Zagonel
    Chiara, Tronconi Maria
    Luca, Di Tommaso
    Laura, Giordano
    Armando, Santoro
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma
    Dorkhom, Stephan Joseph
    Zaman, Shadia
    Thomas, Sheeba K.
    Alexanian, Raymond
    Shah, Jatin J.
    Weber, Donna M.
    Wang, Michael
    Anderson, Martha L.
    Baladandayuthapani, Veerabhadran
    Lin, Yan Heather
    Fu, Min
    Stellrecht, Christine M.
    de Partovi, Claudia Morales
    Gandhi, Varsha V.
    Orlowski, Robert Z.
    BLOOD, 2012, 120 (21)
  • [5] Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.
    Adjei, A. A.
    Sosman, J. A.
    Martell, R. E.
    Dy, G. K.
    Goff, L. W.
    Ma, W. W.
    Horn, L.
    Fetterly, G. J.
    Michael, S. A.
    Means, J. A.
    Chai, F.
    Lamar, M.
    Strauss, G. M.
    Chiang, W.
    Jarboe, J.
    Schwartz, B. E.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
    Pant, S.
    Saleh, M.
    Bendell, J.
    Infante, J. R.
    Jones, S.
    Kurkjian, C. D.
    Moore, K. M.
    Kazakin, J.
    Abbadessa, G.
    Wang, Y.
    Chen, Y.
    Schwartz, B.
    Camacho, L. H.
    ANNALS OF ONCOLOGY, 2014, 25 (07) : 1416 - 1421
  • [7] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Baljevic, Muhamed
    Zaman, Shadia
    Baladandayuthapani, Veerabhadran
    Lin, Yan Heather
    de Partovi, Claudia Morales
    Berkova, Zuzana
    Amini, Behrang
    Thomas, Sheeba K.
    Shah, Jatin J.
    Weber, Donna M.
    Fu, Min
    Cleeland, Charles S.
    Wang, Xin Shelley
    Stellrecht, Christine M.
    Davis, Richard E.
    Gandhi, Varsha
    Orlowski, Robert Z.
    ANNALS OF HEMATOLOGY, 2017, 96 (06) : 977 - 985
  • [8] Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
    Muhamed Baljevic
    Shadia Zaman
    Veerabhadran Baladandayuthapani
    Yan Heather Lin
    Claudia Morales de Partovi
    Zuzana Berkova
    Behrang Amini
    Sheeba K. Thomas
    Jatin J. Shah
    Donna M. Weber
    Min Fu
    Charles S. Cleeland
    Xin Shelley Wang
    Christine M. Stellrecht
    Richard E. Davis
    Varsha Gandhi
    Robert Z. Orlowski
    Annals of Hematology, 2017, 96 : 977 - 985
  • [9] A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
    Wei, Xiaoting
    Zou, Zhengyun
    Zhang, Weizhen
    Fang, Meiyu
    Zhang, Xiaoshi
    Luo, Zhiguo
    Chen, Jing
    Huang, Gang
    Zhang, Peng
    Cheng, Ying
    Liu, Jiwei
    Liu, Jiyan
    Zhang, Junping
    Wu, Di
    Chen, Yu
    Ma, Xiaobiao
    Pan, Hongming
    Jiang, Renbing
    Liu, Xinlan
    Ren, Xiubao
    Tian, Hongqi
    Jia, Zhongwei
    Guo, Jun
    Si, Lu
    EUROPEAN JOURNAL OF CANCER, 2024, 202
  • [10] Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)
    Orlowski, Robert Z.
    Zaman, Shadia
    Thomas, Sheeba K.
    Alexanian, Raymond
    Shah, Jatin J.
    Weber, Donna M.
    Wang, Michael
    Holloway, Ashley N.
    Baladandayuthapani, Veerabhadran
    Lin, Heather Yan
    Fu, Min
    Stellrecht, Christine M.
    de Partovi, Claudia Morales
    Gandhi, Varsha
    BLOOD, 2013, 122 (21)
12345